Sugi Predict

Sugi Predict / Compounds / SCHEMBL3159104

SCHEMBL3159104

SCHEMBL3159104

CC(C)n1cc(C(=O)O)ccc1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCAR3 P49019 4/20 0.49
▸ PTGS2 P35354 2/20 0.44
▸ HPGD P15428 2/20 0.41
▸ HCAR2 Q8TDS4 1/20 0.41
▸ PTGDR2 Q9Y5Y4 3/20 0.41
▸ TP53 P04637 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ KMT2A Q03164 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ LCK P06239 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ TEK Q02763 1/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ CDK5 Q00535 1/20 0.37
▸ CDK5R1 Q15078 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4583848 0.85 PTGS2 (0.40) HCAR3PTGS2HPGDPTGDR2TP53
SCHEMBL28251574 0.83 PARP10 (0.42) HCAR3PTGS2PTGDR2KMT2AALDH1A1
SCHEMBL1504586 0.81 ALDH1A1 (0.48) PTGS2KMT2AALDH1A1SMN1; SMN2GAA
SCHEMBL1852937 0.81 PTGS2 (0.57) PTGS2TP53TSHRSRD5A2
SCHEMBL12890137 0.80 LMNA (0.48) HPGDTP53TSHRKMT2AALDH1A1
SCHEMBL4436629 0.77 OPRD1 (0.45) TSHRGAASRD5A2
SCHEMBL4583984 0.76 PTGS2 (0.35) HCAR3PTGS2HPGDPTGDR2KMT2A
SCHEMBL4583989 0.76 PTGS2 (0.35) HCAR3PTGS2HPGDPTGDR2KMT2A
SCHEMBL22861795 0.76 CA12 (0.49) HPGDTSHRKMT2AALDH1A1SMN1; SMN2
SCHEMBL480137 0.74 CREBBP (0.58) HPGDTP53TSHRKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138525-B2 N-substituted-2-oxodihydropyridine derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-21 — — US claimed
CN-1684954-A N-substituted-2-oxodihydropyridine derivative BANYU PHARMA CO LTD (JP) 2005-10-19 — — CN claimed
EP-1546133-A2 N-SUBSTITUTE-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-06-29 — — EP claimed
US-20050009879-A1 Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders MSD K.K. (JP) 2005-01-13 — — US claimed
WO-2004031175-A2 N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-04-15 — — WO claimed
US-20040072874-A1 N-substituted-2-oxodihydropyridine derivatives MSD K.K. (JP) 2004-04-15 — — US claimed
EP-3768269-B1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2025-08-20 — — EP disclosed
US-12180221-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-12-31 — — US disclosed
US-20240228469-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-11 — — US disclosed
US-20240228469-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-11 — — US disclosed
US-20240217951-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-07-04 — — US disclosed
CN-118084801-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 — — CN disclosed
CN-118084800-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 — — CN disclosed
US-7138525-B2 N-substituted-2-oxodihydropyridine derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-21 — — US disclosed
CN-1684954-A N-substituted-2-oxodihydropyridine derivative BANYU PHARMA CO LTD (JP) 2005-10-19 — — CN disclosed
EP-1546133-A2 N-SUBSTITUTE-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-06-29 — — EP disclosed
US-6869966-B2 N-substituted-2-oxodihydropyridine derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-03-22 — — US disclosed
US-20050009879-A1 Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders MSD K.K. (JP) 2005-01-13 — — US disclosed
WO-2004031175-A2 N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-04-15 — — WO disclosed
US-20040072874-A1 N-substituted-2-oxodihydropyridine derivatives MSD K.K. (JP) 2004-04-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228469-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 HCAR3 2359/4885PTGS2 4143/4885HPGD 3179/4885
US-20240217951-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 HCAR3 1644/4885PTGS2 4357/4885HPGD 3946/4885
US-12180221-B2 Compounds and uses thereof NLN, ACHE, CLN6 HCAR3 830/4885PTGS2 817/4885HPGD 565/4885
US-20050009879-A1 Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders NPY1R, NPY2R, NPY4R HCAR3 82/4885PTGS2 687/4885HPGD 1281/4885
US-20040072874-A1 N-substituted-2-oxodihydropyridine derivatives GPR119, NPY4R, NPY1R HCAR3 127/4885PTGS2 2861/4885HPGD 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.